2022第一四半期: 医薬品開発業界の投資と財務 eBook 英語版

2022年の第1四半期が今年を占うものであったとすれば、医薬品開発市場は雨天のように厳しい時期の装備を整え、身を固めたいと思うかもしれません。Evaluate Vantageチームは、医薬品開発業界の投資と財務に関する調査結果をまとめました。

If the first quarter of 2022 was a bellwether for the rest of year, many in the drug development market might want to don wet weather gear and hunker down for a blustery time. The Evaluate Vantage team has produced its round up of the investment and financial side of the industry and the results make for interesting – if sobering – reading.

Register now to receive your copy.

.

EBOOK HIGHLIGHTS:

Outside big pharma, life remains tough for listed developers
First-quarter biotech risers work hard for the win
Takeover-driven resurgence fails to materialise for biotech
Flotations tank in the first quarter
Venture funding stays strong despite the gloom